20.695
-0.715 (-3.34%)
-0.715 (-3.34%)
Upgrade to Real-Time
Regular Market
Volume | 15,359 |
|
|||||
News | - | ||||||
Day High | 20.98 | Low High |
|||||
Day Low | 20.52 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Avidity Biosciences Inc | RNA | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
20.98 | 20.52 | 20.98 | 21.41 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
166 | 15,359 | $ 20.95 | $ 321,777 | - | 10.89 - 29.25 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
10:05:53 | 1 | $ 20.98 | USD |
Avidity Biosciences Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
$ 1.08B | 52.13M | 43.12M | $ 9.33M | $ - | -2.86 | -6.70 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | $ - | - | - | 0.20% |
Avidity Biosciences News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical RNA Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 19.33 | 22.52 | 19.2611 | 21.79 | 241,229 | 1.37 | 7.06% |
1 Month | 18.21 | 22.52 | 15.2601 | 18.92 | 274,705 | 2.49 | 13.65% |
3 Months | 13.43 | 22.52 | 10.89 | 15.68 | 362,717 | 7.27 | 54.1% |
6 Months | 14.96 | 22.52 | 10.89 | 15.78 | 307,189 | 5.74 | 38.34% |
1 Year | 18.89 | 29.25 | 10.89 | 18.59 | 302,087 | 1.81 | 9.56% |
3 Years | 26.50 | 37.46 | 10.89 | 22.33 | 276,906 | -5.81 | -21.91% |
5 Years | 26.50 | 37.46 | 10.89 | 22.33 | 276,906 | -5.81 | -21.91% |
Avidity Biosciences Description
Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product candidate AOC 1001, is designed to treat a rare monogenic muscle disease. |